Compass Therapeutics, Inc. CMPX

CMPX Company Overview

Compass Therapeutics, Inc. (NASDAQ: CMPX) is a clinical-stage biotechnology company focused on the discovery and development of antibody-based therapeutics for the treatment of cancer. The company operates within the oncology and immunotherapy sectors, with a primary emphasis on developing monoclonal and multispecific antibody candidates designed to engage the immune system against solid tumors and hematologic malignancies. Its lead programs have centered on immune checkpoint modulation and angiogenesis-related pathways, with revenue historically derived primarily from collaboration agreements and financing activities rather than commercial product sales, as the company remains in the clinical development stage.

Compass Therapeutics was founded in 2014 and evolved through the development of a proprietary antibody discovery platform intended to generate multispecific therapeutic antibodies. The company became publicly traded through a merger transaction with a special purpose acquisition company in 2020. Compass has positioned itself as a precision oncology developer focused on differentiated biologic therapies that may address resistance mechanisms and improve efficacy in difficult-to-treat cancers. Public filings and investor materials consistently identify its strategic focus on advancing internally developed oncology assets through clinical trials while selectively pursuing partnerships.